Mirum Pharmaceuticals, Inc. MIRM Asset Acquisition Contingent Consideration Liability Noncurrent
Asset Acquisition Contingent Consideration Liability Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s asset acquisition contingent consideration liability noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s asset acquisition contingent consideration liability noncurrent?
- Mirum Pharmaceuticals, Inc. (MIRM) reported asset acquisition contingent consideration liability noncurrent of $48.26M in Q1 2026.